Introduction to FRA2 and the AP-1 Transcription Factor Family

FRA2 (Fos-Related Antigen 2), encoded by the FOSL2 gene, is a member of the Fos family of proteins that collectively constitute key components of the AP-1 (Activator Protein-1) transcription factor complex. AP-1 is a dimeric transcription factor typically composed of members from the Fos (c-Fos, FosB, Fra-1, FRA2) and Jun (c-Jun, JunB, JunD) protein families. These proteins share a conserved basic leucine-zipper (bZIP) domain that mediates both dimerization and sequence-specific DNA binding to TPA-response elements (TREs) or cAMP-response elements (CREs) within gene promoters and enhancers.

Unlike c-Fos, FRA2 lacks a strong transactivation domain and primarily functions through its capacity to modulate the composition and therefore the transcriptional output of AP-1 complexes. FRA2 expression is regulated by extracellular signals including growth factors, cytokines, and oncogenes, making it a critical node in the integration of extracellular stimuli with nuclear transcriptional responses.

Biological Roles and Pathophysiological Significance

FRA2 participates in a diverse array of biological processes through AP-1-mediated transcriptional regulation. Key areas of documented biological relevance include:

• Oncogenesis: FRA2 is overexpressed in several human cancers. Its role in promoting cell survival, invasion, and metastasis has been studied in melanoma, breast cancer, and other solid tumors. As a component of AP-1, FRA2 can regulate genes encoding matrix metalloproteinases (MMPs) and other pro-tumorigenic factors.
• Immune Regulation: FRA2 influences differentiation and cytokine production in immune cells, including T helper cell subsets, where AP-1 cooperates with NFAT and NF-κB to control inflammatory gene expression programs.
• Bone Homeostasis: FRA2 has been shown to regulate osteoblast differentiation and bone matrix formation. Transgenic studies have indicated that dysregulation of FRA2 expression affects bone density and remodeling.
• Fibrosis: Elevated FRA2 activity has been associated with tissue fibrosis, including pulmonary and systemic sclerosis, through transcriptional activation of collagen and other extracellular matrix genes.
• Neuronal Differentiation: AP-1 complexes containing FRA2 contribute to neuronal gene expression programs, implicating this protein in aspects of nervous system development and plasticity.

These diverse roles make FRA2 an attractive research target across oncology, immunology, rheumatology, and neuroscience disciplines.

Biochemical Properties of Recombinant Human FRA2 Protein

Recombinant Human FRA2 Protein (SKU: rp370511) is produced using recombinant expression technology to deliver a high-purity form of the human FOSL2 protein suitable for in vitro research applications. Researchers should consult the product-specific Certificate of Analysis (CoA) and datasheet for confirmed specifications, as individual lot data may vary. General biochemical characteristics of human FRA2 include:

• Molecular Weight: The full-length human FRA2 protein has a predicted molecular weight of approximately 35–38 kDa, which may appear higher on SDS-PAGE due to post-translational modifications or tag additions in the recombinant form.
• Domain Architecture: FRA2 contains an N-terminal regulatory domain and a C-terminal bZIP domain comprising a basic DNA-binding region and a leucine-zipper dimerization motif.
• Dimerization: FRA2 cannot homodimerize efficiently and requires heterodimerization with Jun family proteins to form transcriptionally active AP-1 complexes capable of high-affinity DNA binding.
• Purity: Recombinant preparations are typically produced to >85% purity as assessed by SDS-PAGE; confirm exact lot purity with CoA.
• Formulation and Storage: Specific buffer composition, stabilizers, and recommended storage conditions (typically −20°C or −80°C with avoidance of repeated freeze-thaw cycles) are detailed in the product datasheet.

Note: Specific molecular weight, purity figures, and lot-specific activity data should be verified against the current product datasheet and CoA provided by Aladdin Scientific.

Research Applications and Experimental Considerations

Recombinant Human FRA2 Protein is suitable for multiple in vitro research applications. Scientists should validate the protein for each specific application in their experimental system. Common applications include:

• Protein–DNA Interaction Studies: Electrophoretic mobility shift assays (EMSAs) and fluorescence polarization assays can be employed to characterize FRA2-containing AP-1 complex binding to TRE or CRE oligonucleotide probes, particularly when FRA2 is pre-complexed with a Jun family partner.
• Protein–Protein Interaction Studies: Pull-down assays, co-immunoprecipitation, and surface plasmon resonance (SPR) experiments can investigate FRA2 heterodimerization with Jun proteins or interactions with transcriptional co-regulators.
• Structural Biology: Recombinant FRA2 provides material for X-ray crystallography or cryo-electron microscopy studies of AP-1 complex architecture.
• Antibody Validation: Recombinant FRA2 serves as a positive control antigen for validating anti-FRA2 antibodies in Western blot, ELISA, or immunoprecipitation formats.
• Biochemical Screening: The protein can be used in compound screening campaigns aimed at disrupting AP-1 dimerization or DNA binding as a potential therapeutic strategy in oncology.

Handling Recommendations: Reconstitute lyophilized protein according to the datasheet instructions. Prepare single-use aliquots to minimize freeze-thaw cycles. Maintain cold-chain integrity throughout handling. All experimental uses should comply with applicable institutional biosafety guidelines.